LIMNW · Liminatus Pharma, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standards Board ("FASB") ASC 205-40, Presentation of Financial Statements—Going Concern, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Latest filings
Liminatus Pharma regained Nasdaq minimum bid price compliance after a 1-for-50 reverse stock split, with closing bid prices above $1.00 per share for 13 consecutive trading days from August 21, 2026 to September 9, 2026, closing the matter.
Read the 8-KTechnicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIMNW
this stock
Liminatus Pharma, Inc.
|
$3.79M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$141.65B | +23.3% | +46.2% | 32.6 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.99B | +20.2% | +20.8% | 20.5 | 2.1% |
|
MRNA
Moderna, Inc.
|
$88.52B | +651.8% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$67.93B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Sep 29, 2026
- This year
- 20
Liminatus Pharma regained Nasdaq minimum bid price compliance after a 1-for-50 reverse stock split, with closing bid prices above $1.00 per share for 13 consecutive trading days from August 21, 2026 to September 9, 2026, closing the matter.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIMNW | -27.9% | -20.0% | — | -27.9% | — |
| SPY | -0.1% | +1.3% | +5.6% | +1.3% | +13.3% |
| vs SPY | -27.8% | -21.3% | — | -29.2% | — |